Mangalam Drugs & Organics IPO Details

p>Incorporated in 1997 (through a merger of its predecessor entities), Mangalam Drugs & Organics Limited (MDOL) is a research-driven pharmaceutical and specialty chemicals manufacturing company with over 30 years of experience, promoted by the Dhoot family and headquartered at Vapi, Gujarat.
The company is engaged in the manufacturing and marketing of bulk drugs, drug intermediates, perfumery chemicals, organic and inorganic chemicals, dye intermediates and specialty chemicals. Its core product portfolio includes anti-malarial bulk drugs such as Chloroquine Phosphate, Chloroquine Sulphate, Amodiaquine Hydrochloride and Amodiaquine Base, along with Nimesulide, Aluminium Chloride (Anhydrous), Phenyl Ethyl Alcohol, Disperse Dye Intermediates and Meta Chloro Aniline. MDOL is one of the largest producers of anti-malarial drugs and Nimesulide in India.
The company operates three manufacturing units located at Vapi (Gujarat) and Sangamner (Maharashtra), with multi-purpose and multi-product production facilities. Its bulk drug manufacturing plant at Vapi holds ISO 9001:2000 certification and WHO-GMP certification (pending renewal). As of March 2005, the company expanded its bulk drug production capacity from 600 MTPA to 960 MTPA. It also maintains a dedicated pilot plant and an in-house R&D facility at Vapi, staffed by 18 personnel, with all manufacturing processes developed entirely in-house.
The company exports to Germany, UK, Switzerland, several African countries, Korea, Turkey, Indonesia, Thailand, Pakistan and Bangladesh, with exports constituting approximately 10% of sales. It holds exclusive supply agreements with three European companies and distributes through 25 domestic agents and 3 overseas agents.
Key strengths include over three decades of brand presence, fully in-house developed processes, strong R&D capabilities, competitive manufacturing costs, multi-purpose production infrastructure, and a Certificate of Suitability from the European Directorate for the Quality of Medicines for its Nimesulide facility. The company has also identified next-generation anti-malarial products including Artesunate, Artemether and Arteether for future manufacturing.